Sandbox/table: Difference between revisions
< Sandbox
No edit summary |
|||
Line 2: | Line 2: | ||
{| style="border: 0px; font-size: 90%; margin: 3px;" align=center | {| style="border: 0px; font-size: 90%; margin: 3px;" align=center | ||
! style="width: 500px;background: #4479BA"|{{fontcolor|#FFF| ''''' | ! style="width: 500px;background: #4479BA"|{{fontcolor|#FFF| '''''Alterations in the coagulation system'''''}} | ||
|- | |- | ||
| style="width: 120px;background: #F5F5F5"| | | style="width: 120px;background: #F5F5F5"| Consumption of [[clotting factors]] | ||
|- | |- | ||
| style="width: 120px;background: #DCDCDC"| | | style="width: 120px;background: #DCDCDC"| Increased concentrations of [[fibrin]] degradation products | ||
|- | |- | ||
| style="width: 120px;background: #F5F5F5"| | | style="width: 120px;background: #F5F5F5"| '''[[Disseminated intravascular coagulation]]''' | ||
|- | |- | ||
|} | |} | ||
{| style="font-size: 85%;" | {| style="font-size: 85%;" | ||
! style="width: 80px; background: #4479BA; text-align: center;"|{{fontcolor|#FFF| | ! style="width: 80px; background: #4479BA; text-align: center;"|{{fontcolor|#FFF|Organ/Tissue}} | ||
! style="width: 720px; background: #4479BA; text-align: center;"| {{fontcolor|#FFF| | ! style="width: 720px; background: #4479BA; text-align: center;"| {{fontcolor|#FFF|Effect}} | ||
|- | |- | ||
| style="background: #F5F5F5; padding: 5px; text-align: center;"| ''' | | style="background: #F5F5F5; padding: 5px; text-align: center;"| '''[[Endothelial cells]]''' | ||
| style="background: #DCDCDC; padding: 5px;"| | | style="background: #DCDCDC; padding: 5px;"| There is no clear evidence of endovascular damage | ||
|- | |- | ||
| style="background: #F5F5F5; padding: 5px; text-align: center;"| ''' | | style="background: #F5F5F5; padding: 5px; text-align: center;"| '''[[Liver]]''' | ||
| style="background: #DCDCDC; padding: 5px;"| | | style="background: #DCDCDC; padding: 5px;"| Causes hepatocellular [[necrosis]] which could impair the synthesis of [[proteins]] of the [[coagulation system]] | ||
|- | |- | ||
| style="background: #F5F5F5; padding: 5px; text-align: center;"| ''' | | style="background: #F5F5F5; padding: 5px; text-align: center;"| '''[[Adrenal cortex]]''' | ||
| style="background: #DCDCDC; padding: 5px;"| | | style="background: #DCDCDC; padding: 5px;"| Affects the synthesis of enzymes responsible for the synthesis of [[steroids]], leading to [[hypotension]], and [[fluid]] and [[electrolytes]] disturbances. | ||
|- | |- | ||
| style="background: #F5F5F5; padding: 5px; text-align: center;"| ''' | | style="background: #F5F5F5; padding: 5px; text-align: center;"| '''[[Lymphatic system]]''' | ||
| style="background: #DCDCDC; padding: 5px;"| [[ | | style="background: #DCDCDC; padding: 5px;"| [[Necrosis of the [[spleen]], [[lymph nodes]] and [[thymus]]; [[Apoptosis]] of [[lymphocytes]] leading to [[lymphopenia]]. | ||
|} | |} | ||
Revision as of 16:06, 20 June 2014
The following table contains the main risk factors for CDI:[1][2][3][2][2]
Alterations in the coagulation system |
---|
Consumption of clotting factors |
Increased concentrations of fibrin degradation products |
Disseminated intravascular coagulation |
Organ/Tissue | Effect |
---|---|
Endothelial cells | There is no clear evidence of endovascular damage |
Liver | Causes hepatocellular necrosis which could impair the synthesis of proteins of the coagulation system |
Adrenal cortex | Affects the synthesis of enzymes responsible for the synthesis of steroids, leading to hypotension, and fluid and electrolytes disturbances. |
Lymphatic system | [[Necrosis of the spleen, lymph nodes and thymus; Apoptosis of lymphocytes leading to lymphopenia. |
table
Diagnostic test | North America | South America | Middle East | Far East |
---|---|---|---|---|
ELISA (serology) detects:
|
† There is a reported prevalence of 15% in the Northeast of the US.
- ↑ Hensgens MP, Goorhuis A, Dekkers OM, Kuijper EJ (2012). "Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics". J Antimicrob Chemother. 67 (3): 742–8. doi:10.1093/jac/dkr508. PMID 22146873.
- ↑ 2.0 2.1 2.2 Knight, Christopher L.; Surawicz, Christina M. (2013). "Clostridium difficile Infection". Medical Clinics of North America. 97 (4): 523–536. doi:10.1016/j.mcna.2013.02.003. ISSN 0025-7125.
- ↑ Planche, Tim (2013). "Clostridium difficile". Medicine. 41 (11): 654–657. doi:10.1016/j.mpmed.2013.08.003. ISSN 1357-3039.